Charles Bennett is an Oncology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
522 N Lecanto Hwy
Lecanto, FL 344618547
Telephone
352-527-0106Provider last certified this registry record 16 Oct 2023.
Clinical trials
- Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
Sponsor: Northwestern University
- Treatment Decision Intervention for Veterans With Prostate Cancer
Sponsor: US Department of Veterans Affairs
- Low Literacy Intervention for Colorectal Cancer Screening
Sponsor: US Department of Veterans Affairs
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Dendreon Pharmaceuticals LLCProgram year20253 payments
- Bayer Healthcare Pharmaceuticals Inc.Program year20252 payments
- TOLMAR, INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
33.3%Opioid Agonist17.8%Oxycodone Hcl29%Oxycodone-Acetaminophen28%Tramadol Hcl24%Fentanyl13%Morphine Sulfate Er6%Part D<11 patientsBenzodiazepine11.1%Alprazolam75%Lorazepam14%Temazepam12%Part D<11 patients+ 2 more classes in this area
Cancer & immunology
31.4%Gonadotropin Releasing Hormone Receptor Agonist14.4%Leuprolide acetate100%Part B, office-administered≥26 patientsAromatase Inhibitor10%Anastrozole80%Letrozole20%Part D<11 patients+ 1 more class in this area
Hormonal (systemic)
12.6%l-Thyroxine12.6%Levothyroxine Sodium87%Synthroid13%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”